Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia

McGahan L
Record ID 32018000334
English
Authors' results and conclusions: Overall, adding ibrutinib to rituximab therapy increases progression-free survival (PFS) and ORR, and reduces the risk of death and progression for symptomatic Waldenström's macroglobulinemia (WM) patients with untreated or recurrent disease. Consistent PFS and overall response rate (ORR) benefit were observed regardless of line, genotype or prognostic score. Further evaluation is needed to identify the role of ibrutinib as first-line versus salvage therapy; monotherapy versus in combination with biologic agents, other small molecules or chemoimmunotherapy; optimal duration of treatment; management of ibrutinib intolerant or resistant patients; and the comparative safety and effectiveness with new Bruton tyrosine kinase (BTK) inhibitors.
Details
Project Status: Completed
URL for project: https://aihta.at/page/horizon-scanning-in-der-onkologie/en
Year Published: 2018
URL for published report: http://eprints.aihta.at/1185/1/DSD_HSO_Nr.85.pdf
URL for additional information: http://eprints.aihta.at/1185/
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Waldenstrom Macroglobulinemia
  • Rituximab
  • Tyrosine Kinase Inhibitors
  • Antineoplastic Combined Chemotherapy Protocols
Keywords
  • Ibrutinib
  • Imbruvica®
  • Rituximab
  • MabThera®
  • Waldenström’s macroglobulinemia
Contact
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name: tarquin.mittermayr@aihta.at
Contact Email: office@aihta.at
Copyright: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.